Nasdaq
$3.69▲ 1.79%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $293.9MShares out 79.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 9.10Pre-market26.09.10 20:298-KKey event#●●●#●●●#●●●
Prelude Therapeutics IncBullish
Prelude Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for PRT13722, a selective KAT6A degrader for the treatment of HR+/HER2- breast cancer. The company expects to initiate patient enrollment for the Phase 1 study in the fourth quarter of 2026, aiming to offer improved efficacy and safety compared to existing dual KAT6A/B inhibitors.…more
$3.69+1.79%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.11Pre-market26.08.11 21:0510-QEarnings
Prelude Therapeutics Inc
프렐류드 테라퓨틱스(Prelude Therapeutics)의 2026년 2분기(6월 30일 마감) 재무제표에 따르면, 현금 및 현금성 자산은 2,633만 달러, 시장성 유가증권은 1억 2,543만 달러를 기록했습니다. 총 자산은 1억 8,936만 달러, 총 부채는 5,563만 달러로 집계되었으며, 2026년 8월 6일 기준 발행 주식 수는 7,980만 3,485주입니다.…more
$3.69+1.79%vs prev closeView filingShare - 8.11Pre-market26.08.11 21:008-KKey event
Prelude Therapeutics Inc
프렐류드 테라퓨틱스는 2026년 2분기 실적 발표를 통해 1,390만 달러의 순손실과 1억 5,520만 달러의 현금 및 유동자산을 보유했다고 보고했습니다. 회사는 4분기 중 KAT6A 분해제 PRT13722의 임상 1상 개시를 계획하고 있으며, 현재 보유 현금으로 2028년 2분기까지 운영이 가능할 것으로 전망합니다.…more
$3.69+1.79%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16After-hours26.10.17 05:01#●●●#●●●
Prelude Therapeutics to Participate in the Chardan Healthcare Conference…more
Prelude Therapeutics announced its participation in the upcoming Chardan Healthcare Conference on October 20. This event is a routine investor relations activity and does not provide immediate material impact on the company's valuation.…more
$3.69+1.79%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.13Pre-market26.10.13 20:22
●●●●●●●● ●●●●● ●●●●●●
Prelude Therapeutics has entered into a supply agreement with Eli Lilly to evaluate its candidate PRT13722 in combination with Lilly's therapies for breast cancer. This clinical collaboration focuses on a Phase 1 trial, with no specific financial terms disclosed regarding the partnership.…more
$3.69+1.79%vs prev closeShareBenzinga - 10.13Pre-market26.10.13 20:01
●●●●●●●● ●●●●● ●●●●●●
Prelude Therapeutics has entered into a clinical trial collaboration and supply agreement with Eli Lilly to evaluate its KAT6A degrader in combination with Lilly's breast cancer therapies. The company plans to initiate patient enrollment for the Phase 1 trial in the fourth quarter of 2026.…more
$3.69+1.79%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report